Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Eocene subsidiary teams with Barcode Nanotech on nanoparticle Aramchol for GI cancers

Galmed R&D has built a new delivery form of Aramchol aimed at liver and gastrointestinal tumours, but the work is preclinical and no commercial terms were disclosed.

16 Nov 2026 · EoCene Ltd. EOCN · Company news

Eocene Ltd. said on 16 November 2026 that its subsidiary Galmed R&D, working with Barcode Nanotech, has created a lipid nanoparticle version of Aramchol. The pitch is a new use for an existing active substance, this time in oncology, though the announcement gives little basis for putting a commercial value on it.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): EoCene Ltd. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →